Timuçin Kaşifoğlu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Timuçin Kaşifoğlu has a total of 236 co-authors. Here are the top co-authors by number of shared publications:
- Nazife Şule Yaşar Bilge
Division of Rheumatology, Department of Internal Medicine, Eskişehir Osmangazi University, Eskişehir, Turkey
24 shared publications - Umut Kalyoncu
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkiye
13 shared publications - Reşit Yıldırım
The Royal Wolverhampton NHS Trust, Wolverhampton, UK
11 shared publications - Cemal Bes
Department of Rheumatology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital , Istanbul
9 shared publications - Mustafa Dinler
Eskisehir Osmangazi University
8 shared publications - Emel Gönüllü
Department of Rheumatology, Sakarya Training and Research Hospital, Sakarya, Türkiye
7 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
The effect of pulmonary nodule presence on disease severity and course in ANCA-associated vasculitis: a multicenter cohort study
- 24 August 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Open AccessThe effect of pulmonary nodule presence on disease severity and course in ANCA-associated vasculitis: a multicenter cohort study
- 19 June 2026
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 81 (5) , 1-10
MEFV variants as phenotypic modifiers in ankylosing spondylitis: a genetic interaction analysis with HLA-B27
1. Ankylosing spondylitis (AS) is a systemic rheumatic condition that primarily causes chronic inflammatory back pain, particularly in young men. The disease primarily affects the sacroiliac joints...
- 19 June 2026
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 81 (5) , 1-10
MEFV variants as phenotypic modifiers in ankylosing spondylitis: a genetic interaction analysis with HLA-B27
1. Ankylosing spondylitis (AS) is a systemic rheumatic condition that primarily causes chronic inflammatory back pain, particularly in young men. The disease primarily affects the sacroiliac joints...
- Open Access
- 7 April 2026
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 21 (5) , 1647-1654
Screening of osteoporosis in patients with ANCA-associated vasculitis (AAV) is quite low: results from a country-wide study
Patients with ANCA-associated vasculitis (AAV) are at increased risk of osteoporosis due to multiple disease- and treatment-related factors. However, real-world data on osteoporosis screening practices in this population remain limited. The aim of this study was to assess osteoporosis screening practices and the prevalence of reduced bone mineral density (BMD) in patients with AAV using a nationwide registry, and to identify factors associated with osteoporosis. This nationwide, retrospective, web-based study was conducted using the Turkish Vasculitis Study Group (TRVaS) database, including patients diagnosed with AAV between January 2000 and December 2023. Patients were evaluated for osteoporosis screening using dual-energy X-ray absorptiometry (DXA) and categorized according to BMD status. Clinical characteristics and potential risk factors were analyzed, and multivariable logistic regression was performed to identify independent predictors of osteoporosis. A total of 528 patients were included (median age 56 years [interquartile range 43–66]; 57.8% male). Of these, 36.2% underwent DXA screening; among screened patients, 40.8% had osteoporosis and 38.7% had osteopenia. In multivariable analysis, older age (odds ratio [OR] 1.03, p = 0.020) and the presence of at least one additional osteoporosis risk factor (OR 2.25, p = 0.049) were independently associated with osteoporosis. This nationwide registry-based study highlights a gap between the recognized risk of osteoporosis in patients with AAV and its implementation in real-world clinical practice. These findings underscore the need for improved screening and comprehensive bone health management strategies in this population.
- 7 April 2026
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 21 (5) , 1647-1654
Open AccessScreening of osteoporosis in patients with ANCA-associated vasculitis (AAV) is quite low: results from a country-wide study
Patients with ANCA-associated vasculitis (AAV) are at increased risk of osteoporosis due to multiple disease- and treatment-related factors. However, real-world data on osteoporosis screening practices in this population remain limited. The aim of this study was to assess osteoporosis screening practices and the prevalence of reduced bone mineral density (BMD) in patients with AAV using a nationwide registry, and to identify factors associated with osteoporosis. This nationwide, retrospective, web-based study was conducted using the Turkish Vasculitis Study Group (TRVaS) database, including patients diagnosed with AAV between January 2000 and December 2023. Patients were evaluated for osteoporosis screening using dual-energy X-ray absorptiometry (DXA) and categorized according to BMD status. Clinical characteristics and potential risk factors were analyzed, and multivariable logistic regression was performed to identify independent predictors of osteoporosis. A total of 528 patients were included (median age 56 years [interquartile range 43–66]; 57.8% male). Of these, 36.2% underwent DXA screening; among screened patients, 40.8% had osteoporosis and 38.7% had osteopenia. In multivariable analysis, older age (odds ratio [OR] 1.03, p = 0.020) and the presence of at least one additional osteoporosis risk factor (OR 2.25, p = 0.049) were independently associated with osteoporosis. This nationwide registry-based study highlights a gap between the recognized risk of osteoporosis in patients with AAV and its implementation in real-world clinical practice. These findings underscore the need for improved screening and comprehensive bone health management strategies in this population.
- 29 October 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Clinical significance of non-infectious procalcitonin elevation in Still’s disease: a predictor of macrophage activation syndrome
Objectives: Still’s disease (SD) is an autoinflammatory disease (AID) that can lead to life-threatening macrophage activation syndrome (MAS). The role of procalcitonin (PCT) in AIDs remains unclear. This study aims to explore the relationship between non-infectious PCT elevation and clinical features of SD. Methods: This retrospective study included patients with SD and absence of infection who had available PCT data. Control groups consisted of patients with confirmed bloodstream infections and age- and sex-matched healthy controls (HCs). A PCT cut-off of 0.5 ng/ml was used. Clinical and laboratory findings were evaluated based on baseline (PCT < 0.5 and PCT ≥ 0.5 groups) and maximum (PCTmax < 0.5 and PCTmax ≥ 0.5 groups) values. Results: The study conducted with 110 patients with SD. Of these, 75 (68%) were in the PCT < 0.5 group and 35 (32%) were in the PCT ≥ 0.5 group, while 63 (57.3%) were in the PCTmax < 0.5 group and 47 (42.7%) were in the PCTmax ≥ 0.5 group. PCT levels were significantly higher in patients with SD compared with HCs and were nearly as elevated in MAS cases as in infection. Frequency of MAS, higher mPouchot scores and increased use of biologic DMARDs, particularly anakinra, were associated with elevated PCT. MAS risk increased 6.4-fold in the PCT ≥ 0.5 group and 7.6-fold in the PCTmax ≥ 0.5 group in univariate analysis, and 4.3-fold and 5.4-fold, respectively, in multivariate analysis. Conclusion: PCT may be a potential marker in AIDs such as SD, even in the absence of infection. Elevated PCT levels may serve as an independent predictor of MAS in SD.
- 29 October 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Clinical significance of non-infectious procalcitonin elevation in Still’s disease: a predictor of macrophage activation syndrome
Objectives: Still’s disease (SD) is an autoinflammatory disease (AID) that can lead to life-threatening macrophage activation syndrome (MAS). The role of procalcitonin (PCT) in AIDs remains unclear. This study aims to explore the relationship between non-infectious PCT elevation and clinical features of SD. Methods: This retrospective study included patients with SD and absence of infection who had available PCT data. Control groups consisted of patients with confirmed bloodstream infections and age- and sex-matched healthy controls (HCs). A PCT cut-off of 0.5 ng/ml was used. Clinical and laboratory findings were evaluated based on baseline (PCT < 0.5 and PCT ≥ 0.5 groups) and maximum (PCTmax < 0.5 and PCTmax ≥ 0.5 groups) values. Results: The study conducted with 110 patients with SD. Of these, 75 (68%) were in the PCT < 0.5 group and 35 (32%) were in the PCT ≥ 0.5 group, while 63 (57.3%) were in the PCTmax < 0.5 group and 47 (42.7%) were in the PCTmax ≥ 0.5 group. PCT levels were significantly higher in patients with SD compared with HCs and were nearly as elevated in MAS cases as in infection. Frequency of MAS, higher mPouchot scores and increased use of biologic DMARDs, particularly anakinra, were associated with elevated PCT. MAS risk increased 6.4-fold in the PCT ≥ 0.5 group and 7.6-fold in the PCTmax ≥ 0.5 group in univariate analysis, and 4.3-fold and 5.4-fold, respectively, in multivariate analysis. Conclusion: PCT may be a potential marker in AIDs such as SD, even in the absence of infection. Elevated PCT levels may serve as an independent predictor of MAS in SD.
- Open Access
- 24 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (43) , e45344
Effect of MEFV mutations and HLA-B27 on clinical findings of familial Mediterranean fever and spondyloarthritis
This study investigated the coexistence of familial Mediterranean fever (FMF) and spondyloarthritis (SpA), aiming to provide a comprehensive understanding of their clinical, radiological, and genetic features. A total of 127 patients with both FMF and SpA were evaluated, with data collected on demographic, clinical, and laboratory characteristics, including human leukocyte antigen (HLA)-B27 status, Mediterranean fever (MEFV) gene variants, and acute phase reactants. Pelvic radiographs and sacroiliac joint magnetic resonance imaging scans were reviewed when available. The median age of the cohort was 39 years (interquartile range: 30–50), and 48% were female, showing an equal sex distribution. Ankylosing spondylitis was the most common SpA subtype (76.4%), followed by nonradiographic axial SpA (10.2%), peripheral SpA (5.5%), undifferentiated SpA (6.3%), and psoriatic arthritis (1.6%). Most patients exhibited intermittent (90.8%) and oligoarticular (76.7%) joint involvement, typically affecting large joints of the lower extremities, while 23.6% had chronic arthritis. Patients with grade 4 sacroiliitis, chronic arthritis, or hip arthroplasty had a longer disease duration ( P < .05). HLA-B27 positivity was identified in 30.4% of patients and was strongly associated with AA amyloidosis (odds ratio = 13.3, 95% confidence interval: 4–43.9). The most frequent MEFV mutation was homozygous M694V (69.3%), followed by M694V/M680I (14.7%) and M680I/V726A (5.3%). MEFV mutations were present in 83.1% of HLA-B27-negative patients. Collectively, these findings indicate that FMF-SpA coexistence defines a distinct clinical and genetic entity characterized by balanced sex distribution, lower HLA-B27 frequency compared to classic SpA, and a strong link between HLA-B27 positivity and amyloidosis risk, underscoring a complex genetic interaction between MEFV variants and HLA-B27 in disease expression.
- 24 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (43) , e45344
Open AccessEffect of MEFV mutations and HLA-B27 on clinical findings of familial Mediterranean fever and spondyloarthritis
This study investigated the coexistence of familial Mediterranean fever (FMF) and spondyloarthritis (SpA), aiming to provide a comprehensive understanding of their clinical, radiological, and genetic features. A total of 127 patients with both FMF and SpA were evaluated, with data collected on demographic, clinical, and laboratory characteristics, including human leukocyte antigen (HLA)-B27 status, Mediterranean fever (MEFV) gene variants, and acute phase reactants. Pelvic radiographs and sacroiliac joint magnetic resonance imaging scans were reviewed when available. The median age of the cohort was 39 years (interquartile range: 30–50), and 48% were female, showing an equal sex distribution. Ankylosing spondylitis was the most common SpA subtype (76.4%), followed by nonradiographic axial SpA (10.2%), peripheral SpA (5.5%), undifferentiated SpA (6.3%), and psoriatic arthritis (1.6%). Most patients exhibited intermittent (90.8%) and oligoarticular (76.7%) joint involvement, typically affecting large joints of the lower extremities, while 23.6% had chronic arthritis. Patients with grade 4 sacroiliitis, chronic arthritis, or hip arthroplasty had a longer disease duration ( P < .05). HLA-B27 positivity was identified in 30.4% of patients and was strongly associated with AA amyloidosis (odds ratio = 13.3, 95% confidence interval: 4–43.9). The most frequent MEFV mutation was homozygous M694V (69.3%), followed by M694V/M680I (14.7%) and M680I/V726A (5.3%). MEFV mutations were present in 83.1% of HLA-B27-negative patients. Collectively, these findings indicate that FMF-SpA coexistence defines a distinct clinical and genetic entity characterized by balanced sex distribution, lower HLA-B27 frequency compared to classic SpA, and a strong link between HLA-B27 positivity and amyloidosis risk, underscoring a complex genetic interaction between MEFV variants and HLA-B27 in disease expression.
- 26 September 2025
- Published by Osmangazi Journal of Medicine in OSMANGAZİ JOURNAL OF MEDICINE
- Vol. 47 (6) , 997-1002
İnflamatuvar Miyopatilerde Miyozit Spesifik Antikorlar ve Klinik Kullanımı: Tek Merkez Deneyimi
Miyozit spesifik antikorlar (MSA), inflamatuvar miyozitleri sınıflandırmada, klinik seyir ve prognozu öngörmede son yıllarda artan sıklıkla kullanılmaktadır. Bu çalışmada merkezimizde takipli inflamatuvar miyopatili hastalar içerisinde miyozit spesifik antikoru çalışılmış hastaların demografik özellikleri, tanıları, klinik bulguları, laboratuvar verileri, antikor profilleri, enfeksiyöz komplikasyon ve malignite gelişimi ve mortalite verileri analiz edildi. Çalışmaya toplam 33 hasta dahil edildi (29 kadın, 4 erkek). Medyan yaş 52 yıl (15-72) ve medyan takip süresi 27 ay (2-250) olarak hesaplandı. Hastaların 15 (%45.4)’i dermatomiyozit tanılı idi. Hastaların 26’sında MSA pozitif saptandı. En sık pozitif saptanan antikorlar Jo-1 (%26,9) ve TIF-1 gamma (%23,1) idi. MSA pozitif inflamatuvar myopatili hastalarda konstitüsyonel semptomlar daha sık görülmekteydi (p:0,011). MSA alt gruplarına (Jo-1 ve diğerleri/ TIF-1 gamma ve diğerleri/ MDA-5 ve diğerleri) göre klinik bulgular değerlendirildiğinde; pulmoner tutulum ile Jo-1 pozitifliği (p<0,001) ve MDA-5 pozitifliği ile kalsinozis (p:0,018) arasında istatistiksel olarak anlamlı bir ilişki bulundu. Toplam 13 hastada infeksiyöz komplikasyonlar ve 3 hastada malignite gelişmişti (serviks, over ve kolorektal karsinom). Çalışmamızda MSA alt gruplarının sıklığı literatür ile benzerlik taşısa da genelleme yapabilmek için geniş hasta popülasyonunda yapılacak çalışmalara ihtiyaç vardır.
- 26 September 2025
- Published by Osmangazi Journal of Medicine in OSMANGAZİ JOURNAL OF MEDICINE
- Vol. 47 (6) , 997-1002
İnflamatuvar Miyopatilerde Miyozit Spesifik Antikorlar ve Klinik Kullanımı: Tek Merkez Deneyimi
Miyozit spesifik antikorlar (MSA), inflamatuvar miyozitleri sınıflandırmada, klinik seyir ve prognozu öngörmede son yıllarda artan sıklıkla kullanılmaktadır. Bu çalışmada merkezimizde takipli inflamatuvar miyopatili hastalar içerisinde miyozit spesifik antikoru çalışılmış hastaların demografik özellikleri, tanıları, klinik bulguları, laboratuvar verileri, antikor profilleri, enfeksiyöz komplikasyon ve malignite gelişimi ve mortalite verileri analiz edildi. Çalışmaya toplam 33 hasta dahil edildi (29 kadın, 4 erkek). Medyan yaş 52 yıl (15-72) ve medyan takip süresi 27 ay (2-250) olarak hesaplandı. Hastaların 15 (%45.4)’i dermatomiyozit tanılı idi. Hastaların 26’sında MSA pozitif saptandı. En sık pozitif saptanan antikorlar Jo-1 (%26,9) ve TIF-1 gamma (%23,1) idi. MSA pozitif inflamatuvar myopatili hastalarda konstitüsyonel semptomlar daha sık görülmekteydi (p:0,011). MSA alt gruplarına (Jo-1 ve diğerleri/ TIF-1 gamma ve diğerleri/ MDA-5 ve diğerleri) göre klinik bulgular değerlendirildiğinde; pulmoner tutulum ile Jo-1 pozitifliği (p<0,001) ve MDA-5 pozitifliği ile kalsinozis (p:0,018) arasında istatistiksel olarak anlamlı bir ilişki bulundu. Toplam 13 hastada infeksiyöz komplikasyonlar ve 3 hastada malignite gelişmişti (serviks, over ve kolorektal karsinom). Çalışmamızda MSA alt gruplarının sıklığı literatür ile benzerlik taşısa da genelleme yapabilmek için geniş hasta popülasyonunda yapılacak çalışmalara ihtiyaç vardır.
- Open Access
- 29 April 2025
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 7 (2) , 81-86
Are Male Patients with Behçet’s Disease Unlucky? : An Analysis of 506 Behçet Patients
Background Behçet's Disease (BD) is characterized by oral and genital ulcers, arthritis, skin manifestations, uveitis, gastrointestinal tract, and central nervous system involvement. Although it is known to be more severe in men, there are studies in the literature with conflicting results regarding gender and the distribution of clinical findings. This study aimed to examine the relationship between clinical findings and gender in BD patients and to compare our results with the literature. Methods 506 patients diagnosed with Behçet's disease were included in the study. Demographic data, laboratory, and clinical findings of the patients were obtained retrospectively from hospital records. The distribution of clinical findings according to gender was evaluated. Results A total of 280 males (55.3%) and 226 females (44.7%) were included in the study. There was no significant difference between male and female patients regarding age at diagnosis (p=0.662). Genital ulcer (47.6% vs 52.4%, p=0.011), superficial thrombophlebitis (20.9% vs 79.1%, p=0.002), uveitis (33.7% vs 66.3%, p=0.02), deep vein thrombosis (22.5% vs 77.5%, p=0.00) and pulmonary artery aneurysm (11.1% vs 88.9%, p=0.046) were more common in males. There was no significant difference between the sexes in other clinical findings, HLA B5, and pathergy positivity. Conclusion Gender impacts the clinical manifestations of BD and should be considered in patient follow-up. However, it is a heterogeneous disease, other factors may certainly affect the emergence of clinical findings.
- 29 April 2025
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 7 (2) , 81-86
Open AccessAre Male Patients with Behçet’s Disease Unlucky? : An Analysis of 506 Behçet Patients
Background Behçet's Disease (BD) is characterized by oral and genital ulcers, arthritis, skin manifestations, uveitis, gastrointestinal tract, and central nervous system involvement. Although it is known to be more severe in men, there are studies in the literature with conflicting results regarding gender and the distribution of clinical findings. This study aimed to examine the relationship between clinical findings and gender in BD patients and to compare our results with the literature. Methods 506 patients diagnosed with Behçet's disease were included in the study. Demographic data, laboratory, and clinical findings of the patients were obtained retrospectively from hospital records. The distribution of clinical findings according to gender was evaluated. Results A total of 280 males (55.3%) and 226 females (44.7%) were included in the study. There was no significant difference between male and female patients regarding age at diagnosis (p=0.662). Genital ulcer (47.6% vs 52.4%, p=0.011), superficial thrombophlebitis (20.9% vs 79.1%, p=0.002), uveitis (33.7% vs 66.3%, p=0.02), deep vein thrombosis (22.5% vs 77.5%, p=0.00) and pulmonary artery aneurysm (11.1% vs 88.9%, p=0.046) were more common in males. There was no significant difference between the sexes in other clinical findings, HLA B5, and pathergy positivity. Conclusion Gender impacts the clinical manifestations of BD and should be considered in patient follow-up. However, it is a heterogeneous disease, other factors may certainly affect the emergence of clinical findings.
- 24 December 2024
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (2) , 831-838
Frequency of severe infections in rheumatic disease patients receiving bDMARDs post-kidney transplantation: a multicenter study
Objectives To evaluate the incidence and characteristics of severe infections in rheumatic patients receiving biologic disease-modifying anti-rheumatic drugs (bDMARDs) after kidney transplantation. Methods This multicenter, retrospective study included 38 patients who had undergone kidney transplantation and received bDMARDs for rheumatic diseases. Demographic, clinical, and treatment data were collected. Severe infections were defined as those requiring hospitalization, and the incidence of severe infections was calculated per 100 patient years. Risk factors for severe infections were analyzed. Results Of the 38 patients (median age 40.5 years), 52.6% experienced severe infections, with a total of 39 severe infection episodes. The incidence of severe infections was 26.2 per 100 patient-years. The most common infections were urinary tract infections (43.5%) and pneumonia (30.8%). Familial Mediterranean Fever (FMF) was the most common rheumatic disease (57.9%), and the median disease duration was 18.5 years. Most patients (68.4%) were using IL-1 inhibitors, and 31.6% were on anti-TNF therapy. There was no significant difference between patients with and without infections in terms of gender, pre-transplant biological therapy use, or type of biological therapy used. Four patients (11%) died from infection-related complications, including coronavirus disease-19 (COVID-19). Conclusion Rheumatic patients receiving bDMARDs post-kidney transplantation have a high risk of severe infections. The concurrent use of immunosuppressive therapy and bDMARDs may further increase this risk, necessitating close infection monitoring and management. Key Points • Rheumatic patients treated with biologic disease-modifying anti-rheumatic drugs (bDMARDs) following kidney transplantation face a heightened risk of severe infections. • The concurrent use of immunosuppressive therapy and bDMARDs may further increase this risk. • Individualized treatment strategies are essential to balance the benefits of bDMARDs with the potential for severe infectious complications.
- 24 December 2024
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (2) , 831-838
Frequency of severe infections in rheumatic disease patients receiving bDMARDs post-kidney transplantation: a multicenter study
Objectives To evaluate the incidence and characteristics of severe infections in rheumatic patients receiving biologic disease-modifying anti-rheumatic drugs (bDMARDs) after kidney transplantation. Methods This multicenter, retrospective study included 38 patients who had undergone kidney transplantation and received bDMARDs for rheumatic diseases. Demographic, clinical, and treatment data were collected. Severe infections were defined as those requiring hospitalization, and the incidence of severe infections was calculated per 100 patient years. Risk factors for severe infections were analyzed. Results Of the 38 patients (median age 40.5 years), 52.6% experienced severe infections, with a total of 39 severe infection episodes. The incidence of severe infections was 26.2 per 100 patient-years. The most common infections were urinary tract infections (43.5%) and pneumonia (30.8%). Familial Mediterranean Fever (FMF) was the most common rheumatic disease (57.9%), and the median disease duration was 18.5 years. Most patients (68.4%) were using IL-1 inhibitors, and 31.6% were on anti-TNF therapy. There was no significant difference between patients with and without infections in terms of gender, pre-transplant biological therapy use, or type of biological therapy used. Four patients (11%) died from infection-related complications, including coronavirus disease-19 (COVID-19). Conclusion Rheumatic patients receiving bDMARDs post-kidney transplantation have a high risk of severe infections. The concurrent use of immunosuppressive therapy and bDMARDs may further increase this risk, necessitating close infection monitoring and management. Key Points • Rheumatic patients treated with biologic disease-modifying anti-rheumatic drugs (bDMARDs) following kidney transplantation face a heightened risk of severe infections. • The concurrent use of immunosuppressive therapy and bDMARDs may further increase this risk. • Individualized treatment strategies are essential to balance the benefits of bDMARDs with the potential for severe infectious complications.
- 31 October 2024
- Published by Caleo in Rheumatology Quarterly
- Vol. 2 (3) , 144-146
DIGITAL ULCERATION FOLLOWING GEMCITABIN PLUS CISPLATIN CHEMOTHERAPY IN A SYSTEMIC SCLEROSIS PATIENT WITH LUNG ADENOCARCINOMA
Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by fibrosis and vascular dysfunction in the skin and visceral organ systems. Digital ulceration is one of the major cause of morbidity. Although its pathogenesis has not been fully elucidated, structural and functional disturbances in small vessels are considered one of the major mechanisms. While cold exposure is considered the most important inciting factor for the development of digital ulceration, drugs and physical trauma are other described triggering factors. Herein, we report a case with SSc diagnosis who developed digital ulcers following gemcitabine and cisplatin chemotherapy for lung adenocarcinoma.
- 31 October 2024
- Published by Caleo in Rheumatology Quarterly
- Vol. 2 (3) , 144-146
DIGITAL ULCERATION FOLLOWING GEMCITABIN PLUS CISPLATIN CHEMOTHERAPY IN A SYSTEMIC SCLEROSIS PATIENT WITH LUNG ADENOCARCINOMA
Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by fibrosis and vascular dysfunction in the skin and visceral organ systems. Digital ulceration is one of the major cause of morbidity. Although its pathogenesis has not been fully elucidated, structural and functional disturbances in small vessels are considered one of the major mechanisms. While cold exposure is considered the most important inciting factor for the development of digital ulceration, drugs and physical trauma are other described triggering factors. Herein, we report a case with SSc diagnosis who developed digital ulcers following gemcitabine and cisplatin chemotherapy for lung adenocarcinoma.
- Open Access
- 24 July 2024
- Published by Academician Publishing
Romatolojide Güncel Tedaviler
Analjezikler, Non-Steroid Anti-İNFLAMATUAR İlaçlar ve Kortikosteroidler Duygu KURTULUŞ Biyolojik Olmayan Hastalık Modifiye Edici Antiromatizmal ilaçlar Ali Nail DEMİR Romatolojide Biyolojik Tedavi Ajanları İsmail UÇAR İmmunsupresifler ve Diğer İlaçlar Önay GERÇİK Romatolojide İntravenöz İmmünoglobulin Uygulamaları Hüseyin Ali ÖZTÜRKAlper YILDIRIM Romatolojide Plazmaferez Uygulamaları Alper YILDIRIM Erken Artrit ve Palindromik Romatizma: Güncel Tedavi Neslihan GÖKÇEN Romatoid Artrit: Güncel Tedavi Zeynep KAYA Meryem CAN Romatoid Artritte Ekstra-Artiküler Tutulum Tedavisi Zübeyde UĞURLU Atalay DOĞRU Tekrarlayıcı Seronegatif Pİtting Ödemli Simetrik Sinovit (R3SPE) Sendromu Tedavi Yönetimi Berkan ARMAĞAN Erişkin Başlangıçlı Still Hastalığına Güncel Yaklaşım Ahmet KOR Şükran ERTEN Enfeksiyöz Artritler: Bakteriyel Artritler, Lyme Artriti, Viral Artritler, Mikobakteriyel, Brucella, Fungal Ve Parazitik Artritler: Güncel Tedavi Fatma TUNCER KURU Ankilozan Spondilit ve Non-Radyografik Aksiyel Spondiloartrit: Güncel Tedavi Dilek SOLMAZ Periferik Spondiloartrit: Güncel Tedavi Fatih SARITAŞ Psöriatik Artrit: Güncel Tedavi Selda ÇELİK Enteropatik Artrit Tedavisi Mete PEKDİKER Reaktif Artrit: Güncel Tedavi Özgül SOYSAL GÜNDÜZ Jüvenil İdyopatik Artrit Tedavisinde Güncel Yaklaşımlar Kenan BARUT Elif KILIÇ KÖNT Özgür KASAPÇOPUR Sistemik Lupus Eritematozusda Güncel Tedavi Hamide Kart KÖSEOĞLU Sjögren Sendromunda Güncel Tedavi Yaklaşımları Pınar TALU ERTEN Antifosfolipid Sendromu Tedavisi Pınar AKYÜZ DAĞLI Ahmet OMMA Gebelikte Sistemik Lupus Eritematozus ve Antifosfolipid Antikor Sendromu: Güncel Tedavi Senar ŞAN Ayten YAZICI Kutanöz Lupus Eritematosus: Güncel Tedavisi Tuğba TEHÇİ Sistemik Skleroz Tedavisi Yasemin YALÇINKAYA Raynaud Fenomeninin Güncel Tedavisi Duygu TEMİZ KARADAĞ İdiopatik İnflamatuar Myopati Güncel Tedavi Figen TARHAN Anti-Sentetaz Sendromu Emel GÖNÜLLÜ Mix Konnektif Doku Hastalığında Güncel Tedavi İpek TÜRK Undiferansiye Bağ Dokusu Hastalığı ve Overlap Sendromlar Güncel Tedavi Derya KAŞKARİ Poliarteritis Nodosa Güncel Tedavisi Esra KAYACAN ERDOĞAN Dev Hücreli Arterit ve Polimyaljiya Romatika Tedavisi Vedat GERDAN Granülomatöz Polianjiitis’te Güncel Tedavi Özlem DOĞAN AĞBUGA Diğer Anca İlişkili Vaskülitlerde Güncel Tedavi Emrah KOÇ Takayasu Arteriti Güncel Tedavisi Sema KAYMAZ TAHRA Fatma ALİBAZ ÖNER Klinik Tutulumlara Göre Behçet Hastalığında Güncel Tedavi Yüksel MARAŞ Kawasaki Hastalığı Güncel Tedavi Rabia Miray KIŞLA EKİNCİ İmmun Kompleks Küçük Damar Vaskülitlerinde Güncel Tedavi Elif EDİBOĞLU Sarkoidoz: Güncel Tedavi Müge AYDIN TUFAN Relapsing Polikondrit Suade Özlem BADAK IgG4 İlişkili Hastalık: Güncel Tedavi Nazife Şule YAŞAR BİLGE Timuçin KAŞİFOĞLU Ailevi Akdeniz Ateşi: Güncel Tedavi Zeynep TOKER DİNÇER Serdal UĞURLU Henoch Schönlein Purpurası (HSP) Özge Altuğ GÜCENMEZ FMF Dışı Otoenflamatuar Hastalıklar: Güncel Tedavi Amra ADROVİÇ Mehmet YILDIZ Özgür KASAPÇOPUR Otoinflamatuar Hastalıklarda Aa Amiloidoz Güncel Tedavi Safiye BAKKALGerçek CAN Gut: Güncel Tedavi Gezmiş KİMYON CPPD Güncel Tedavi Fatih Necip ARICI Alper YILDIRIM Konnektif Doku Hastalığı İlişkili Pulmoner Arteriyel Hipertansiyon Tedavisi Alper SARI Romatolojik Hastalıklarda İnterstisyel Akciğer Hastalığı: Güncel Tedavi Zevcet YILMAZ Romatolojik Hastalıklarda Aşılama Mehmet Ali AŞIK Gebe, Emziren Ve Gebelik Planı Olan Romatoloji Hastalarında Paternal ve Maternal İlaç Kullanımı Sercan GÜCENMEZ
- 24 July 2024
- Published by Academician Publishing
Open AccessRomatolojide Güncel Tedaviler
Analjezikler, Non-Steroid Anti-İNFLAMATUAR İlaçlar ve Kortikosteroidler Duygu KURTULUŞ Biyolojik Olmayan Hastalık Modifiye Edici Antiromatizmal ilaçlar Ali Nail DEMİR Romatolojide Biyolojik Tedavi Ajanları İsmail UÇAR İmmunsupresifler ve Diğer İlaçlar Önay GERÇİK Romatolojide İntravenöz İmmünoglobulin Uygulamaları Hüseyin Ali ÖZTÜRKAlper YILDIRIM Romatolojide Plazmaferez Uygulamaları Alper YILDIRIM Erken Artrit ve Palindromik Romatizma: Güncel Tedavi Neslihan GÖKÇEN Romatoid Artrit: Güncel Tedavi Zeynep KAYA Meryem CAN Romatoid Artritte Ekstra-Artiküler Tutulum Tedavisi Zübeyde UĞURLU Atalay DOĞRU Tekrarlayıcı Seronegatif Pİtting Ödemli Simetrik Sinovit (R3SPE) Sendromu Tedavi Yönetimi Berkan ARMAĞAN Erişkin Başlangıçlı Still Hastalığına Güncel Yaklaşım Ahmet KOR Şükran ERTEN Enfeksiyöz Artritler: Bakteriyel Artritler, Lyme Artriti, Viral Artritler, Mikobakteriyel, Brucella, Fungal Ve Parazitik Artritler: Güncel Tedavi Fatma TUNCER KURU Ankilozan Spondilit ve Non-Radyografik Aksiyel Spondiloartrit: Güncel Tedavi Dilek SOLMAZ Periferik Spondiloartrit: Güncel Tedavi Fatih SARITAŞ Psöriatik Artrit: Güncel Tedavi Selda ÇELİK Enteropatik Artrit Tedavisi Mete PEKDİKER Reaktif Artrit: Güncel Tedavi Özgül SOYSAL GÜNDÜZ Jüvenil İdyopatik Artrit Tedavisinde Güncel Yaklaşımlar Kenan BARUT Elif KILIÇ KÖNT Özgür KASAPÇOPUR Sistemik Lupus Eritematozusda Güncel Tedavi Hamide Kart KÖSEOĞLU Sjögren Sendromunda Güncel Tedavi Yaklaşımları Pınar TALU ERTEN Antifosfolipid Sendromu Tedavisi Pınar AKYÜZ DAĞLI Ahmet OMMA Gebelikte Sistemik Lupus Eritematozus ve Antifosfolipid Antikor Sendromu: Güncel Tedavi Senar ŞAN Ayten YAZICI Kutanöz Lupus Eritematosus: Güncel Tedavisi Tuğba TEHÇİ Sistemik Skleroz Tedavisi Yasemin YALÇINKAYA Raynaud Fenomeninin Güncel Tedavisi Duygu TEMİZ KARADAĞ İdiopatik İnflamatuar Myopati Güncel Tedavi Figen TARHAN Anti-Sentetaz Sendromu Emel GÖNÜLLÜ Mix Konnektif Doku Hastalığında Güncel Tedavi İpek TÜRK Undiferansiye Bağ Dokusu Hastalığı ve Overlap Sendromlar Güncel Tedavi Derya KAŞKARİ Poliarteritis Nodosa Güncel Tedavisi Esra KAYACAN ERDOĞAN Dev Hücreli Arterit ve Polimyaljiya Romatika Tedavisi Vedat GERDAN Granülomatöz Polianjiitis’te Güncel Tedavi Özlem DOĞAN AĞBUGA Diğer Anca İlişkili Vaskülitlerde Güncel Tedavi Emrah KOÇ Takayasu Arteriti Güncel Tedavisi Sema KAYMAZ TAHRA Fatma ALİBAZ ÖNER Klinik Tutulumlara Göre Behçet Hastalığında Güncel Tedavi Yüksel MARAŞ Kawasaki Hastalığı Güncel Tedavi Rabia Miray KIŞLA EKİNCİ İmmun Kompleks Küçük Damar Vaskülitlerinde Güncel Tedavi Elif EDİBOĞLU Sarkoidoz: Güncel Tedavi Müge AYDIN TUFAN Relapsing Polikondrit Suade Özlem BADAK IgG4 İlişkili Hastalık: Güncel Tedavi Nazife Şule YAŞAR BİLGE Timuçin KAŞİFOĞLU Ailevi Akdeniz Ateşi: Güncel Tedavi Zeynep TOKER DİNÇER Serdal UĞURLU Henoch Schönlein Purpurası (HSP) Özge Altuğ GÜCENMEZ FMF Dışı Otoenflamatuar Hastalıklar: Güncel Tedavi Amra ADROVİÇ Mehmet YILDIZ Özgür KASAPÇOPUR Otoinflamatuar Hastalıklarda Aa Amiloidoz Güncel Tedavi Safiye BAKKALGerçek CAN Gut: Güncel Tedavi Gezmiş KİMYON CPPD Güncel Tedavi Fatih Necip ARICI Alper YILDIRIM Konnektif Doku Hastalığı İlişkili Pulmoner Arteriyel Hipertansiyon Tedavisi Alper SARI Romatolojik Hastalıklarda İnterstisyel Akciğer Hastalığı: Güncel Tedavi Zevcet YILMAZ Romatolojik Hastalıklarda Aşılama Mehmet Ali AŞIK Gebe, Emziren Ve Gebelik Planı Olan Romatoloji Hastalarında Paternal ve Maternal İlaç Kullanımı Sercan GÜCENMEZ